STAT modulators

Details STAT modulators STAT modulators

2005-04-26

2005-04-26

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C549S200000, C548S535000

Reexamination Certificate

active

06884782

ABSTRACT:
The present invention provides compounds, compositions and methods for the inhibition or treatment of conditions or disorders modulated by the STAT transcription factors, particularly STAT4 and STAT6. Additionally, the compounds are useful for the diagnosis of conditions dependent on STAT signaling.

REFERENCES:
patent: 5591825 (1997-01-01), McKnight et al.
patent: 5618693 (1997-04-01), McKnight et al.
patent: 5639858 (1997-06-01), Hoey et al.
patent: 5710266 (1998-01-01), McKnight et al.
patent: 5716622 (1998-02-01), Darnell, Jr. et al.
patent: 5731155 (1998-03-01), Schreiber et al.
patent: 5756700 (1998-05-01), Hoey et al.
patent: 6207391 (2001-03-01), Wu et al.
patent: 6426331 (2002-07-01), McKinney et al.
patent: WO 9705162 (1997-02-01), None
patent: WO 9831704 (1998-07-01), None
patent: WO 9924442 (1999-05-01), None
patent: WO 9950283 (1999-10-01), None
patent: WO 00027802 (2000-05-01), None
patent: WO 0183517 (2001-11-01), None
English Abstract of JP 10175964, issued Jun. 30, 1998 to Sumitomo Seiyaku KK.
English Abstract of JP 10175965, issued Jun. 30, 1998 to Sumitomo Seiyaku KK.
English Abstract of JP 11106340, issued Apr. 20, 1999 to Sumitomo Seiyaku KK.
English Abstract of JP 11116481, issued Apr. 27, 1999 to Sumitomo Seiyaku KK.
English Abstract of JP 2000 229959 A1, issued Aug. 22, 2000 to Sumitomo Chem. Co. Ltd.
Corry et al., J. Exp. Med., 183:109-117 (1996).
Durbin, J.E.: Cell 84(3):443-50 (1996).
Foster, P.S.: Clin. Experimental Allergy 29(1):12-16 (1999).
Henderson: J. Immunol. 164:1086-95 (2000).
Kuperman: J Exp. Med. 187:939 (1998).
Mattes et al., J. Immunol., 167:1683-92 (2001).
Mikita: J. Biol.Chem. 273:17634 (1998).
Oshima and Puri, FASEB Journal 15(6):122-144 (2001).
Perez-G. et al., J. Immunol., 168:1428-34 (2002).
Tomkinson, A.: Am. J. Resp. Crit. Care Med. 160(4):1283-91 (1999).
Trifilieff, A.: Br. J. Pharmacol. 130(7):1581-8 (2000).
Wang, L.H.: Blood 95(4):1249-57 (2000).
Anonymous, “STAT antibodies” Research Diagnostics, pp. 1-9, Mar. 26, 1998.
Anonymous, “Stat sampler kit” The 1998 Online Antibody Catalog, Transduction Laboratories, 5 pages Mar. 29, 1998.
Anonymous, “The jak-STAT mechanism of signal transduction” The Cytokine Bulletin pp. 1-6 (1995) at ≦http://www.mdsystems.com/asp/b≧ (visited on Jan. 8, 2003).
Blommers et al., “Transferred cross-correlated relaxation complements transferred NOE: Structureof an IL-4R-derived peptide bound to STAT-6” J. Am. Chem. Soc. 121(9):1949-1953 (1999).
Carpenter, “Receptor tyrosine kinase substrate: src homology domains and signal transduction” FASEB J. 6:3283-3289 (1992).
Darnell et al., “Jak-Stat pathways and transcriptional activation in response to IFNs and other extracellular signalling proteins” Science 264:1415 (1994).
Hou et al., “An Interleukin-4-induced transcription factor: IL-4 stat” Science 265:1701-1706 (1994).
Ihle et al., “Signaling by the cytokine receptor superfamily: JAKs and STATs” Trends Biochem Sci. 19:222-227 (1994).
Ihle et al., “Jaks and Stats in signaling by the cytokine receptor superfamily” Trends Genetics 11:69-74 (1995).
Kaplan et al., “Impaired IL-12 responses and enhanced development of Th2 cells in stat4-deficient mice” Nature 382:174-177 (1996).
Kaplan, M. et al., “Sta6 is required for mediating responses to IL-4 and for the development of TH2 cells” Immunity 4:313-319 (1998).
Martin, et al., “Sulfonic acid enkephalin: Binding specificity to rat brain opiate receptors” Neuropeptides 6:293-302 (1985).
Myers et al., “The IRS-1 signaling system” Trends in Biochem. Sci. 19:289-293 (1994).
Oshima et al., “A novel interleukin-13 antagonist that blocks the biological activity of human interleukin-13 in immune and nonimmune cells” FASEB Journal 15(6):122-144 (2001).
Pawson, T. “Protein modules and signaling networks” Nature 373:573-580 (1995).
Quelle et al., “Cloning of murine Stat6 and Human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis” Mol. Cell. Biol. 15:336-3343 (1995).
Ryan, J. et al. “Growth and gene expression are predominantly controlled by distinct regions of the human IL-4 receptor” Immunity 4:123-132 (1996).
Schindler, C. et al., “Transcriptional responses to polypeptide ligands: The JAK-STAT pathway” Annu. Rev. Biochem. 64:621-51 (1995).
Schlessinger, J. “SH2/SH3 signaling proteins” Curr. Opin. In. Gen. and Dev. 4:25-30 (1994).
Shuai et al., “Polypeptide signaling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins” Nature 366:580-583 (1993).
Thierfelder et al., “Requirement for stat4 in interleukin-12 mediated responses of natural killer and T cells” Nature 382:171-174 (1996).
Wang, H. et al., “IL-4 function can be transferred to the IL-2 receptor by tyrosine containing sequences found in the IL-4 receptor alpha chain” Immunity 4:113-131 (1996).
Yamamoto et al., “cDNA cloning, expression and chromosome mapping of the human STAT4 gene: both STAT4 and STAT1 genes are mapped to 2q32.2→q32.3” Cytogenet Cell Genet. 77:207-210 (1997).
Yao et al., “Direct interaction of STAT4 with the IL-12 receptor” Archives of Biochemistry and Biophysics 368(1):147-155 (1999).
Zhong et al., “Stat3 and Stat4: Members of the family of signal transducers and activators of transcription” Proc. Natl. Acad. Sci. USA 91:4806-4810 (1994).

Affiliated with

Also associated with

Rating

STAT modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with STAT modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and STAT modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3367087